Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,356.944 |
Reported balance
After 2026-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-14 · Exercise / conversion · Acquired 204 · Balance 7,356.944 F1: Includes a total of 21 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 252.944 shares held in the ESPP which has been increased by 0.005 shares due to a rounding calculation of previously issued fractional shares. |
| Common StockSEC Table I · non-derivative | Direct | 7,576.944 |
Reported balance
After 2026-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-14 · Exercise / conversion · Acquired 220 · Balance 7,576.944 |
| Common StockSEC Table I · non-derivative | Direct | 7,877.944 |
Reported balance
After 2026-02-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-14 · Exercise / conversion · Acquired 301 · Balance 7,877.944 |
| Common StockSEC Table I · non-derivative | Direct | 8,244.944 |
Reported balance
After 2026-02-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-02-14 · Exercise / conversion · Acquired 367 · Balance 8,244.944 F2: Represents Restricted Stock Units ('RSU') that were granted on February 14, 2025, were deferred in accordance with the Issuer's Deferred Compensation Plan and have vested. Upon vesting, these RSUs were recorded in an account under such Plan and represents a contingent right to receive one share of Issuer common stock that is payable as soon as practicable after the reporting person's termination of employment with the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 8,023.944 |
Reported balance
After 2026-02-14 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-02-14 · Tax withholding · Disposed 221 · Balance 8,023.944 F3: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. F4: Includes 367 vested but deferred RSUs. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 5,361 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Grant · Acquired 5,361 · Balance 5,361 F6: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 162 |
Reported balance
After 2026-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-12 · Grant · Acquired 162 · Balance 162 F7: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,262 |
Reported balance
After 2026-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-12 · Grant · Acquired 1,262 · Balance 1,262 F8: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,620 |
Reported balance
After 2026-02-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-12 · Grant · Acquired 1,620 · Balance 1,620 F9: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,101 |
Reported balance
After 2026-02-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-14 · Exercise / conversion · Disposed 367 · Balance 1,101 F10: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-14 · Exercise / conversion · Disposed 204 · Balance 0 F11: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 220 |
Reported balance
After 2026-02-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-02-14 · Exercise / conversion · Disposed 220 · Balance 220 F12: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 602 |
Reported balance
After 2026-02-14 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-02-14 · Exercise / conversion · Disposed 301 · Balance 602 F13: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 592 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 592 F5: Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a total of 21 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 252.944 shares held in the ESPP which has been increased by 0.005 shares due to a rounding calculation of previously issued fractional shares.
F2: Represents Restricted Stock Units ('RSU') that were granted on February 14, 2025, were deferred in accordance with the Issuer's Deferred Compensation Plan and have vested. Upon vesting, these RSUs were recorded in an account under such Plan and represents a contingent right to receive one share of Issuer common stock that is payable as soon as practicable after the reporting person's termination of employment with the Issuer.
F3: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
F4: Includes 367 vested but deferred RSUs.
F5: Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.
F6: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
F7: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
F8: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027.
F9: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027.
F10: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan.
F11: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.
F12: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
F13: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2023 Filed Nov 8, 2023 22:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 706 | $141.60 | $99,969.60 |
DisclosureSEC source: 0000874716-23-000131 · wk-form4_1699481341.xml · nonDerivative · entry 2 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,213.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 22:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 462 | $67.85 | $31,346.70 |
DisclosureSEC source: 0000874716-23-000131 · wk-form4_1699481341.xml · nonDerivative · entry 1 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,507.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on September 29, 2023. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 7,080 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-23-000103 · wk-form4_1691442284.xml · derivative · entry 8 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,286 Underlying: Common Stock · 7,080 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant of option to buy 8,366 shares of Issuer common stock that vested in five annual installments beginning February 14, 2020. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 7,435 | $0.00 Strike: $178.26 | $0.00 |
DisclosureSEC source: 0000874716-23-000103 · wk-form4_1691442284.xml · derivative · entry 7 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,435 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant of option to buy 9,434 shares of Issuer common stock that vested in five annual installments beginning February 14, 2019. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,512 | $0.00 Strike: $141.60 | $0.00 |
DisclosureSEC source: 0000874716-23-000103 · wk-form4_1691442284.xml · derivative · entry 6 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,512 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant of option to buy 10,386 shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 16,027 | $510.00 | $8,173,770.00 |
DisclosureSEC source: 0000874716-23-000103 · wk-form4_1691442284.xml · nonDerivative · entry 4 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,033.9875 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 7,080 | $206.94 | $1,465,135.20 |
DisclosureSEC source: 0000874716-23-000103 · wk-form4_1691442284.xml · nonDerivative · entry 3 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,060.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 7,435 | $178.26 | $1,325,363.10 |
DisclosureSEC source: 0000874716-23-000103 · wk-form4_1691442284.xml · nonDerivative · entry 2 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,980.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,512 | $141.60 | $214,099.20 |
DisclosureSEC source: 0000874716-23-000103 · wk-form4_1691442284.xml · nonDerivative · entry 1 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,545.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| May 05, 2023 Filed May 8, 2023 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $484.00 | $484,000.00 |
DisclosureSEC source: 0000874716-23-000041 · wf-form4_168357967838709.xml · nonDerivative · entry 1 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,021.9875 F1 · balance_after: Includes 14.7030 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · derivative · entry 12 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F7 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · derivative · entry 11 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,371 Underlying: Common Stock · 161 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F7 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · derivative · entry 10 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,532 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F7 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · derivative · entry 9 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,705 Underlying: Common Stock · 181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F7 · price: Not applicable. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · derivative · entry 8 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,886 Underlying: Common Stock · 196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F7 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 275 | $503.65 | $138,503.75 |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · nonDerivative · entry 6 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,007.2845 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · nonDerivative · entry 5 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,282.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · nonDerivative · entry 4 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,078.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · nonDerivative · entry 3 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,917.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 181 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · nonDerivative · entry 2 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,744.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:51 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 196 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003218 · doc1.xml · nonDerivative · entry 1 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,563.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002392 · doc1.xml · derivative · entry 5 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,082 Underlying: Common Stock · 880 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F6 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002392 · doc1.xml · derivative · entry 4 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,236 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002392 · doc1.xml · derivative · entry 3 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,236 Underlying: Common Stock · 6,236 shares Expires 2033-02-07 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 15 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,202 Underlying: Common Stock · 161 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F11 · price: Not applicable. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 14 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F11 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 13 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,536 Underlying: Common Stock · 181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F11 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 12 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,717 Underlying: Common Stock · 196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F11 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 11 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,913 Underlying: Common Stock · 211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F11 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 10 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,124 Underlying: Common Stock · 816 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F11 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 197 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 9 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197 Underlying: Common Stock · 197 shares Expires 2032-02-13 F11 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 7,009 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · derivative · entry 8 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,009 Underlying: Common Stock · 7,009 shares Expires 2032-02-13 F11 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1 | $505.53 | $505.53 |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · nonDerivative · entry 6 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,312.2845 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · nonDerivative · entry 5 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,588.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · nonDerivative · entry 4 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,427.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 181 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · nonDerivative · entry 3 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,254.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 196 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · nonDerivative · entry 2 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,073.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:23 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004782 · doc1.xml · nonDerivative · entry 1 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,877.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 19 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2021 and December 31, 2021. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,436 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · derivative · entry 25 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,512 Underlying: Common Stock · 4,436 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · price: Not applicable. F21 · derivative.exercise_date: Grant of option to buy 10,386 shares of Issuer common stock that vest in five annual installments beginning February 14, 2018. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,091 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · derivative · entry 24 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,091 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · price: Not applicable. F20 · derivative.exercise_date: Grant of option to buy 10,749 shares of Issuer common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,472 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · derivative · entry 23 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462 Underlying: Common Stock · 1,472 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · price: Not applicable. F19 · derivative.exercise_date: Grant of option to buy 2,072 shares of Issuer common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1 | $693.17 | $693.17 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 21 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,647.2845 Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 60 | $692.56 | $41,553.70 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 20 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,648.2845 F17 · price: Represents the weighted average sales price of the shares sold ranging from a low of $692.125 to a high of $692.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $691.19 | $69,119.20 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 19 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,708.2845 F16 · price: Represents the weighted average sales price of the shares sold ranging from a low of $690.45 to a high of $691.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 153 | $689.51 | $105,495.05 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 18 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,808.2845 F15 · price: Represents the weighted average sales price of the shares sold ranging from a low of $689.25 to a high of $690.18 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 299 | $688.51 | $205,864.61 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 17 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,961.2845 F14 · price: Represents the weighted average sales price of the shares sold ranging from a low of $688.09 to a high of $688.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 84 | $687.59 | $57,757.82 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 16 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,280.2845 F13 · price: Represents the weighted average sales price of the shares sold ranging from a low of $687.05 to a high of $687.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 60 | $692.65 | $41,558.80 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 15 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,344.2845 F12 · price: Represents the weighted average sales price of the shares sold ranging from a low of $692.27 to a high of $692.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $691.35 | $69,135.20 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 14 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,404.2845 F11 · price: Represents the weighted average sales price of the shares sold ranging from a low of $691.19 to a high of $691.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 30 | $690.33 | $20,709.75 |
DisclosureSEC source: 0001567619-21-014512 · doc1.xml · nonDerivative · entry 13 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,504.2845 F10 · price: Represents the weighted average sales price of the shares sold ranging from a low of $690.17 to a high of $690.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.